Metformin effects in non-diabetic individuals
Pro Research Analysisby 
Searched over 200M research papers
Metformin Effects in Non-Diabetic Individuals: Glucose Metabolism and Diabetes Prevention
Metformin and Glucose Production in Non-Diabetics
Research shows that metformin, while primarily used to lower blood sugar in people with type 2 diabetes, has notable effects in non-diabetic individuals as well. In a controlled trial, non-diabetic participants who took metformin for 90 days experienced an increase in both endogenous glucose production (EGP) and glucose rate of disappearance (R_d) by about 30%. This is surprising because metformin is generally thought to reduce glucose production in the liver, but in non-diabetics, it appears to increase both glucose production and uptake, without affecting fasting plasma glucose or body composition. These findings challenge the traditional view of how metformin works, especially in people without diabetes or with only mild glucose issues .
Metformin for Diabetes Prevention in At-Risk Non-Diabetics
Metformin has been studied extensively for its ability to prevent the progression from prediabetes (non-diabetic hyperglycemia) to type 2 diabetes. Large trials, such as the Diabetes Prevention Program (DPP), found that metformin reduced the risk of developing diabetes by about 31% over three years in people with impaired glucose tolerance, with the effect being strongest in younger and heavier individuals. The benefit, though reduced, persisted for up to 22 years in follow-up studies. Metformin also helped maintain weight loss over the long term. However, while metformin lowers the risk of developing diabetes, improvements in long-term clinical outcomes for non-diabetic individuals have not yet been clearly demonstrated .
Metformin and Metabolic Effects in Non-Diabetics
Studies comparing diabetics and non-diabetics found that metformin does not significantly change glucose disposal or lactate metabolism in non-diabetic individuals. In non-diabetics, metformin did not enhance insulin-mediated glucose uptake or affect lactate turnover, suggesting its main metabolic effects are more pronounced in those with impaired glucose regulation 35. In diabetics, metformin primarily works by reducing hepatic glucose output and inhibiting gluconeogenesis, but these effects are not as evident in non-diabetic controls 35.
Non-Glycemic and Protective Effects
Beyond blood sugar control, metformin is being explored for other health benefits. For example, it is being considered for use in conditions like obesity and polycystic ovary syndrome, and it may have protective effects on the kidneys and cardiovascular system, even in non-diabetic settings 67. There is also evidence suggesting metformin may help preserve brain volume in elderly diabetic individuals, which could have implications for cognitive health, though this has not been specifically studied in non-diabetics .
Conclusion
In summary, metformin in non-diabetic individuals does not lower fasting blood sugar but can increase both glucose production and uptake. Its most established benefit in non-diabetics is reducing the risk of developing type 2 diabetes in those at high risk, especially when combined with lifestyle changes. Other potential protective effects are being investigated, but more research is needed to confirm long-term benefits in non-diabetic populations 1235+2 MORE.
Sources and full results
Most relevant research papers on this topic